149 related articles for article (PubMed ID: 9104940)
21. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
22. Telomerase activity and alterations in telomere length in human brain tumors.
Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N
Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755
[TBL] [Abstract][Full Text] [Related]
23. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
24. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
25. Differential telomerase expression in human primary intracranial tumors.
DeMasters BK; Markham N; Lillehei KO; Shroyer KR
Am J Clin Pathol; 1997 May; 107(5):548-54. PubMed ID: 9128267
[TBL] [Abstract][Full Text] [Related]
26. [X-ray computed tomographic aspects of malignant meningioma and meningeal hemangiopericytoma].
Dufresne MC; Bédard F
Can Assoc Radiol J; 1996 Aug; 47(4):279-87. PubMed ID: 8696997
[TBL] [Abstract][Full Text] [Related]
27. Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas.
Yew A; Trang A; Nagasawa DT; Spasic M; Choy W; Garcia HM; Yang I
J Clin Neurosci; 2013 Jan; 20(1):17-22. PubMed ID: 22743042
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of allelic losses and telomerase activity in meningiomas.
Leuraud P; Dezamis E; Aguirre-Cruz L; Taillibert S; Lejeune J; Robin E; Mokhtari K; Boch AL; Cornu P; Delattre JY; Sanson M
J Neurosurg; 2004 Feb; 100(2):303-9. PubMed ID: 15098535
[TBL] [Abstract][Full Text] [Related]
29. Telomerase in brain tumors.
Falchetti ML; Larocca LM; Pallini R
Childs Nerv Syst; 2002 Apr; 18(3-4):112-7. PubMed ID: 11981616
[TBL] [Abstract][Full Text] [Related]
30. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
31. MIB-1 staining index of pediatric meningiomas.
Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
[TBL] [Abstract][Full Text] [Related]
32. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
33. Management of benign and aggressive intracranial meningiomas.
Akeyson EW; McCutcheon IE
Oncology (Williston Park); 1996 May; 10(5):747-56; discussion 756-9. PubMed ID: 8738830
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and long-term outcomes of pediatric spinal meningiomas.
Wu L; Yang C; Liu T; Fang J; Yang J; Xu Y
J Neurooncol; 2017 Jun; 133(2):347-355. PubMed ID: 28432584
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema.
Nordqvist AC; Smurawa H; Mathiesen T
J Neurosurg; 2001 Nov; 95(5):839-44. PubMed ID: 11702875
[TBL] [Abstract][Full Text] [Related]
37. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
Palma L; Celli P; Franco C; Cervoni L; Cantore G
J Neurosurg; 1997 May; 86(5):793-800. PubMed ID: 9126894
[TBL] [Abstract][Full Text] [Related]
38. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications.
Cai DX; Banerjee R; Scheithauer BW; Lohse CM; Kleinschmidt-Demasters BK; Perry A
J Neuropathol Exp Neurol; 2001 Jun; 60(6):628-36. PubMed ID: 11398839
[TBL] [Abstract][Full Text] [Related]
39. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
J Neurosurg; 2005 Sep; 103(3):508-17. PubMed ID: 16235684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
